InflammaPD

Acute inflammation is a fundamental physiological process that is essential for healing damaged or infected tissues. By contrast, chronic inflammation is implicated in numerous pathologies, and when it affects the central nervous system, it significantly contributes to neurodegenerative mechanisms. In this context, neuroinflammation — particularly the activation of microglia — plays a crucial role in the progression of Parkinson's disease. The persistent stimulation of microglia, which is induced by the accumulation of alpha-synuclein, leads to hyperactivation, characterised by oxidative stress and functional impairment. This promotes neuronal damage.

Therefore, an effective neuroprotective strategy must aim to modulate microglial activity without compromising its physiological roles in immune defence and tissue repair. However, continuous inhibition of these cells is not clinically sustainable as it would interfere with their ability to resolve infections and repair damage. To overcome this limitation, the project seeks to develop an innovative gene therapy system that can release anti-inflammatory molecules on demand in a controlled and targeted manner. This approach will enable the selective reduction of chronic inflammatory states while preserving the protective functions of microglia. The ultimate goal is to slow neurodegeneration and improve the safety and efficacy of treatment.